Equities analysts expect vTv Therapeutics Inc. (NASDAQ:VTVT) to report $200,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for vTv Therapeutics’ earnings, with the highest sales estimate coming in at $200,000.00 and the lowest estimate coming in at $190,000.00. vTv Therapeutics posted sales of $40,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 400%. The business is scheduled to report its next quarterly earnings results on Wednesday, November 1st.

According to Zacks, analysts expect that vTv Therapeutics will report full-year sales of $200,000.00 for the current year, with estimates ranging from $200,000.00 to $30.60 million. For the next year, analysts forecast that the business will post sales of $15.10 million per share, with estimates ranging from $200,000.00 to $30.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.02. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.19 million.

Several research analysts recently commented on VTVT shares. Zacks Investment Research downgraded shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, April 27th. HC Wainwright set a $13.00 price objective on shares of vTv Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 4th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 price objective on shares of vTv Therapeutics in a report on Friday. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $14.30.

Shares of vTv Therapeutics (VTVT) opened at 4.04 on Tuesday. The stock has a 50 day moving average of $4.73 and a 200-day moving average of $5.35. vTv Therapeutics has a 52-week low of $4.00 and a 52-week high of $7.50. The firm’s market capitalization is $132.56 million.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its stake in vTv Therapeutics by 24.3% in the fourth quarter. Renaissance Technologies LLC now owns 60,900 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 11,901 shares in the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in vTv Therapeutics during the first quarter valued at about $917,000. Essex Investment Management Co. LLC purchased a new stake in vTv Therapeutics during the first quarter valued at about $261,000. Bank of New York Mellon Corp boosted its stake in vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,305 shares in the last quarter. Finally, Sphera Funds Management LTD. boosted its stake in vTv Therapeutics by 50.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock valued at $1,965,000 after buying an additional 100,000 shares in the last quarter. 11.12% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/08/analysts-expect-vtv-therapeutics-inc-vtvt-will-announce-quarterly-sales-of-200000-00.html.

About vTv Therapeutics

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.